Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.59 and traded as high as $8.06. Cumberland Pharmaceuticals shares last traded at $7.85, with a volume of 137,133 shares traded.

Wall Street Analysts Forecast Growth

CPIX has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Cumberland Pharmaceuticals Trading Down 1.7%

The company has a current ratio of 0.95, a quick ratio of 0.79 and a debt-to-equity ratio of 0.25. The company has a market cap of $104.71 million, a PE ratio of -14.27 and a beta of 0.09. The company has a fifty day simple moving average of $6.10 and a two-hundred day simple moving average of $4.61.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The business had revenue of $9.13 million during the quarter, compared to analysts’ expectations of $8.50 million.

Cumberland Pharmaceuticals Dividend Announcement

The company also recently announced a dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, July 23rd will be paid a dividend of $1.50 per share.

Institutional Trading of Cumberland Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new position in shares of Cumberland Pharmaceuticals during the 4th quarter worth about $1,358,000. Dimensional Fund Advisors LP lifted its stake in Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the last quarter. Bridgeway Capital Management LLC lifted its stake in Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares during the last quarter. Marshall Wace LLP acquired a new position in Cumberland Pharmaceuticals in the fourth quarter valued at approximately $192,000. Finally, Geode Capital Management LLC boosted its holdings in Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares in the last quarter. 15.51% of the stock is owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.